The Role of Bismuth in the Treatment of Gastroduodenal Pathology (Literature Review and Own Researches)

Yu.M. Stepanov, L.M. Mosiichuk

Abstract


The article presents the history of colloidal bismuth subcitrate and considers the basic mechanisms of its effects on the gastric mucosa, both cytoprotective and anti-helicobacter. The recent data of the worldwide researches are given on the use of the bismuth subcitrate as a component of antibacterial therapy in order to improve the effectiveness of the eradication, especially under the resistance to the basic drugs. The results of own researches are also shown, they are dedicated to the dynamics of structural adjustment of the gastric mucosa in patients with chronic atrophic gastritis for 3 years after the eradication of H.pylori. The use of first-line therapy with the addition of the drug De-Nol allowed to achieve eradication in 94.3 % of patients and positive microstructural changes of the gastric mucosa.

Keywords


bismuth subcitrate; eradication of Helicobacter pylori; chronic atrophic gastritis

References


Глинка Н.Л. Общая химия / Н.Л. Глинка. — ​М., 2004. — 702 с.

Yang N. Biological chemistry of antimony and bismuth / N. Yang, H. Sun // Biological chemistry of arsenic, antimony and bismuth. — ​Singapore: John Wiley & Sons Ltd., 2011. — 400 р.

Salvador J.A. Bismuth compounds in medicinal chemistry / J.A. Salvador, S.A. Figueiredo, R.M. Pinto, S.M. Silvestre // Future Med. Chem. — 2012. — ​Vol. 4, № 11. — ​P. 1495-1523.

Kuever R.A. Bismuth compounds / R.A. Kuever, L.M. Wheeler. United States Patent US2414650. Publication Date: January 21, 1947. Application Number: US48796443A.

Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications. United States Patent US8389021. Publication Date: 03.05.2013.

Lee S.P. A potential mechanism of action of colloidal bismuth subcitrate; diffusion barrier to hydrochloric acid / S.P. Lee // Scand. J. Gastroenterol. — 1982. — ​Vol. 17, Suppl. 80. — ​P. 17-21.

Turner N.C. The influence of native porcine gastric mucus gel on hydrogen ion diffusion: the effect of potentially ulcerogenic agents / N.C. Turner, G.P. Martin, C. Marriott // J. Pharm. Pharmacol. — 1985. — ​Vol. 37, № 11. — ​P. 776-780.

Soutar R.L. Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro / R.L. Soutar, S.B. Coghill // Gastroenterology. — 1986. — ​Vol. 91, № 1. — ​P. 84-93.

Mendis A.H.W. Helicobacter pylori and bismuth / A.H.W. Mendis, B.J. Marshall // Biological chemistry of arsenic, antimony and bismuth. — ​Singapore: John Wiley & Sons Ltd., 2011. — 400 р.

Coghill S.B. The ultrastructural localisation of De-Nol (colloidal tripotassium dicitrato-bismuthate — ​TDB) in the upper gastrointestinal tract of man and rodents following oral and instrumental administration / S.B. Coghill, D. Hopwood, S. McPherson, S. Hislop // J. Pathol. —1983. — ​Vol. 139, № 2. — ​P. 105-114.

Hollanders D. Mucus secretion in gastric ulcer patients treated with tripotassium dicitrato bismuthate (De-Nol) / D. Hollanders, S.M. Morrissey, J. Mehta // Br. J. Clin. Pract. — 1983. — ​Vol. 37, № 3. — ​P. 112-114.

Hall D.W.R. Protective properties of colloidal bismuth subcitrate on the gastric mucosa / D.W.R. Hall, W.E. van de Hoven // Scand. J. Gastroenterol. — 1986. — ​Vol. 21, Suppl. 122. — ​P. 11-13.

Effects of colloidal bismuth subcitrate and aluminum hydroxide on gastric and duodenal levels of prostaglandin E2 / R. Estela, A. Feller, C. Backhouse [et al.] // Rev. Med. Chil. — 1984. — ​Vol. 112, № 10. — ​P. 975-981.

De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism / S.J. Konturek, J. Bilski, N. Kwiecien [et al.] // Gut. — 1987. — ​Vol. 28, № 12. — ​P. 1557-1563.

Crampton J.R. Effect of certain ulcer-healing agents on amphibian gastroduodenal bicarbonate secretion / J.R. Crampton, L.C. Gibbons, W.D. Rees // Scand. J. Gastroenterol. — 1986. — ​Vol. 21, Suppl. 125. — ​P. 113-118.

Roberts N.B. Effect of cyclo-alkyl lactamimides upon amylase, lipase, trypsin and chymotrypsin / N.B. Roberts, W.H. Taylor, C. Westcott // J. Pharm. Pharmacol. — 1982. — ​Vol. 34, № 6. — ​P. 397-400.

Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol) / J.H. Baron, J. Barr, J. Batten [et al.] // Gut. — 1986. — ​Vol. 27, № 5. — ​P. 486-490.

Pharmacological properties of colloidal bismuth subcitrate (CBS, De-Nol) / J. Wieriks, W. Hespe, K.D. Jaitly [et al.] // Scand. J. Gastroenterol. — 1982. — ​Vol. 17, Suppl. 80. — ​P. 11-16.

Stiel D. Uptake and subcellular localisation of bismuth in the gastrointestinal mucosa of rats after short term administration of colloidal bismuth subcitrate / D. Stiel, D.J. Murray, T.J. Peters // Gut. — 1985. — ​Vol. 26, № 4. — ​P. 364-368.

Does the duodenal cell ever return to normal? A comparison between treatment with cimetidine and denol / M.G. Moshal, M.A. Gregory, C. Pillay, J.M. Spitaels // Scand. J. Gastroenterol. — 1979. — ​Vol. 14, Suppl. 54. — ​P. 48-51.

Bismuth subsalicylate increases intracellular Ca2+, MAP-kinase activity, and cell proliferation in normal human gastric mucous epithelial cells / J. Gilster, K. Bacon, K. Marlink [et al.] // Dig. Dis. Sci. — 2004. — ​Vol. 49, № 3. — ​P. 370-378.

Bismuth ions inhibit the biological activity of non-amidated gastrins in vivo / S. Kovac, S.W. Loh, S. Lachal [et al.] // Biochem. Pharmacol. — 2012. — ​Vol. 83, № 4. — ​P. 524-530.

Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts / C.W. Stratton, R.R. Warner, P.E. Coudron, N.A. Lilly // J. Antimicrob. Chemother. — 1999. — ​Vol. 43, № 5. — ​P. 659-666.

A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori / R.G. Ge, X. Sun, Q. Gu [et al.] // J. Biol. Inorg. Chem. — 2007. — ​Vol. 12, № 6. — ​P. 831-842.

Lambert J.R. The actions of bismuth in the treatment of Helicobacter pylori infection / J.R. Lambert, P. Midolo // Aliment. Pharmacol. Ther. — 1997. — ​Vol. 11, Suppl. 1. — ​P. 27-33.

Ge R.G. Bioinorganic chemistry of bismuth and antimony: target sites of metallodrugs / R.G. Ge, H.Z. Sun // Acc. Chem. Res. — 2007. — ​Vol. 40, № 4. — ​P. 267-274.

Xia W. Functional disruption of HypB, a GTPase of Helicobacter pylori, by bismuth / W. Xia, H. Li, H. Sun // Chem. Commun. (Camb.). — 2014. — ​Vol. 50, № 13. — ​P. 1611-1614.

Inhibition of alcohol dehydrogenase by bismuth / L. Jin, K.Y. Szeto, L. Zhang [et al.] // J. Inorg. Biochem. — 2004. — ​Vol. 98, № 8. — ​P. 1331-1337.

A triple and quadruple therapy with doxycycline and bismuth for first-line treatment of Helicobacter pylori infection: a pilot study / A.F. Ciccaglione, L. Cellini, L. Grossi [et al.] // Helicobacter. — 2015. — № 20(5). — 390-396.

Role of bismuth in the eradication of Helicobacter pylori / H. Alkim, A.R. Koksal, S. Boga [et al.] // Am. J. Ther. — 2016. [Epub ahead of print]

First-line bismuth-containing five-day concomitant quintuple therapy for Helicobacter pylori eradication / C. Dolapcioglu, M. Sayiner, E.E. Akkus [et al.] // Helicobacter. — 2016. — № 21(2). — ​P. 100-105.

The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study / B. Ergül, Z. Doğan, M. Sarikaya, L. Filik // Helicobacter. — 2013. — № 18(6). — ​P. 454-458.

Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial / A. Kefeli, S. Basyigit, A.O. Yeniova [et al.] // Bosn. J. Basic Med. Sci. — 2016. — ​Vol. 16(1). — ​P. 52-57.

Seven-day bismuth-based quadruple therapy as an initial treatment for Helicobacter pylori infection in a high metronidazole resistant area / R.K. Vilaichone, H. Prapitpaiboon, P. Gamnarai [et al.] / Asian Pac. J. Cancer Prev. — 2015. — ​Vol. 16(14). — ​P. 6089-6092.

Prapitpaiboon H. High efficacy of levofloxacin-dexlansoprazole-based quadruple therapy as a first line treatment for Helicobacter pylori eradication in Thailand / H. Prapitpaiboon, V. Mahachai, R.K. Vilaichone // Asian Pac. J. Cancer Prev. — 2015. — ​Vol. 16(10). — ​P. 4353-4356.

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication / Sun Q., Liang X., Zheng Q. [et al.] // Helicobacter. — 2010. — ​Vol. 15(3). — ​P. 233-238.

Malfertheiner P. Infection: bismuth improves PPI-based triple therapy for H. pylori eradication / P. Malfertheiner // Nat. Rev. Gastroenterol. Hepatol. — 2010. — ​Vol. 7(10). — ​P. 538-539.

Фадеенко Г.Д. Место висмута субцитрата в комплексной терапии пациентов с язвенной болезнью, ассоциированной с Нelicobacter pylori / Г.Д. Фадеенко, Е.В. Колесникова // Сучасна гастроентерологія. — 2015. — № 1. — ​С. 37-43.

Дорофеев А.Э. Коллоидный субцитрат висмута в лечении хеликобактерной инфекции / А.Э. Дорофеев, Н.Н. Руденко, А.В. Сибилев // Гастроентерологія. — 2016. — № 1(59). — ​С. 26-29.

Палій І.Г. До питання ефективності ерадикаційної терапії з використанням три- та чотирикомпонентних схем: місце препаратів вісмуту / І.Г. Палій, С.В. Заїка, А.П. Піддубецька // Сучасна гастроентерологія. — 2014. — № 2. — ​С. 77-84.

Атрофический гастрит как предраковое состояние желудка: новый взгляд на старую проблему / Е.А. Коган, В.П. Тюрин, В.Д. Креймер [и др.] // Клин. мед. — 2011. — № 1. — ​С. 34-37.

Бабак О.Я. Морфологические изменения слизистой оболочки желудка при хроническом атрофическом гастрите после проведения антихеликобактерной терапии / Бабак О.Я., Фадеенко Г.Д. // Сучасна гастроентерологія. — 2007. — № 6(38). — ​С. 36-39.

Regression of atrophy in patients with atrophic body gastritis following Helicobacter pylori treatment / L. Vannella, E. Lahner, C. Bordi [et al.] // Gut. — 2009. — ​Vol. 58 (Suppl. 2). — ​P. 72.

Атрофічний гастрит: оптимізація діагностики, класифікації та прогнозування: Метод. рекомендації / Ю.М. Степанов, М.Ю. Зак, Л.М. Мосійчук, Ю.А. Гайдар. — ​К., 2012. — 32 с.




DOI: https://doi.org/10.22141/2308-2097.3.61.2016.79151

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru